Altimmune Inc (ALT) concluded trading on Thursday at a closing price of $4.4, with 9.36 million shares of worth about $41.2 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -39.31% during that period and on July 10, 2025 the price saw a loss of about -7.17%. Currently the company’s common shares owned by public are about 81.11M shares, out of which, 80.26M shares are available for trading.
Stock saw a price change of -10.20% in past 5 days and over the past one month there was a price change of -26.05%. Year-to-date (YTD), ALT shares are showing a performance of -36.14% which decreased to -38.97% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.90 but also hit the highest price of $11.16 during that period. The average intraday trading volume for Altimmune Inc shares is 5.44 million. The stock is currently trading -22.19% below its 20-day simple moving average (SMA20), while that difference is down -21.67% for SMA50 and it goes to -31.52% lower than SMA200.
Altimmune Inc (NASDAQ: ALT) currently have 81.11M outstanding shares and institutions hold larger chunk of about 47.37% of that.
The stock has a current market capitalization of $356.87M and its 3Y-monthly beta is at -0.00. It has posted earnings per share of -$1.25 in the same period. It has Quick Ratio of 15.82 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALT, volatility over the week remained 8.06% while standing at 11.69% over the month.
Stock’s fiscal year EPS is expected to rise by 7.66% while it is estimated to decrease by -21.25% in next year. EPS is likely to shrink at an annualized rate of 2.73% for next 5-years, compared to annual growth of 3.48% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on July 10, 2025 offering a Sell rating for the stock and assigned a target price of $1 to it. On January 08, 2025, Stifel Initiated their recommendations, while on November 12, 2024, UBS Initiated their ratings for the stock with a price target of $26. Stock get a Neutral rating from Guggenheim on April 29, 2024.
